Latest & greatest articles for prostate cancer screening

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer screening or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer screening and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer screening

21. Prostate-Specific Antigen (PSA)?based population screening for prostate cancer: an evidence-based analysis

Prostate-Specific Antigen (PSA)?based population screening for prostate cancer: an evidence-based analysis Prostate-Specific Antigen (PSA)–based population screening for prostate cancer: an evidence-based analysis Prostate-Specific Antigen (PSA)–based population screening for prostate cancer: an evidence-based analysis Pron G Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been (...) made for the HTA database. Citation Pron G. Prostate-Specific Antigen (PSA)–based population screening for prostate cancer: an evidence-based analysis. Toronto: Health Quality Ontario (HQO). Ontario Health Technology Assessment Series; 15(10). 2015 Authors' conclusions None of the systematic reviews of the randomized controlled screening trials for PC found a statistically significant reduction in relative risk of PC mortality or overall mortality with PSA-based population screening programs

2015 Health Technology Assessment (HTA) Database.

22. Harms of Prostate-Specific Antigen (PSA) screening in prostate cancer: a rapid review

of Cancer; Humans; Male; Mass Screening /adverse effects; Prostate-Specific Antigen; Prostatic Neoplasms Language Published English Country of organisation Canada Province or state Ontario English summary An English language summary is available. Address for correspondence Evidence Development and Standards, Health Quality Ontario, 130 Bloor Street West, 10th floor, Toronto, Ontario Canada M5S 1N5 Email: EDSinfo@hqontario.ca AccessionNumber 32015000712 Date abstract record published 09/06/2015 Health (...) Harms of Prostate-Specific Antigen (PSA) screening in prostate cancer: a rapid review Harms of Prostate-Specific Antigen (PSA) screening in prostate cancer: a rapid review Harms of Prostate-Specific Antigen (PSA) screening in prostate cancer: a rapid review Fergenbaum J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Fergenbaum J. Harms

2015 Health Technology Assessment (HTA) Database.

23. Factors associated with prostate cancer screening behavior among men over 50 in Fasa, Iran, based on the PRECEDE model Full Text available with Trip Pro

Factors associated with prostate cancer screening behavior among men over 50 in Fasa, Iran, based on the PRECEDE model Prostate cancer is one of the most common and lethal cancers in the world. The incidence of prostate cancer has been increasing in recent years. The purpose of this study was to investigate factors associated with prostate cancer screening behaviors among men over 50 in Fasa, Iran, based on the PRECEDE model.In this cross-sectional study, 400 men over 50 were studied in Fasa (...) , Iran. Data were collected via a questionnaire on demographic characteristics, such as age, number of children, occupation, education, marital status, smoking, and prostate cancer screening behaviors. Data were analyzed using SPSS software, version 16. Independent samples t-test and the Pearson Product Moment correlation coefficient were used for the statistical analyses.Men in the study had little knowledge (34.11±8.22) and attitude (28.23±7.23) about prostate cancer and screening behavior

2015 Electronic physician

24. Prostate-Specific Antigen?Based Population Screening for Prostate Cancer

cancer (PC) is the most commonly diagnosed non-cutaneous cancer in men and their second or third most common cause of cancer-related deaths. Prostate cancer is a heterogeneous disease with a variable natural history ranging from low-risk tumours (unlikely to threaten men’s quality or length of life) to highly aggressive forms. The etiology of PC is largely unknown and the established risk factors—older age, ethnicity, and family history—explain only a fraction of variation in disease occurrence (...) , with the majority of cancers being low risk and organ PSA-Based Population Screening for Prostate Cancer: OHTAC Recommendation. May 2015; pp. 1–5 3 confined. The detection of intermediate-risk tumours was similar in the study groups and, although the detection of high-grade tumours declined with subsequent screening, the progression of PC to metastasis during follow-up did not decline, potentially limiting the effectiveness of screening programs. Overall, although the probability of having a PC detected

2015 Health Quality Ontario

25. Randomised controlled trial: Although the evidence is not clear, decreases in prostate cancer mortality in specific subgroups of men may be due to screening

Randomised controlled trial: Although the evidence is not clear, decreases in prostate cancer mortality in specific subgroups of men may be due to screening Although the evidence is not clear, decreases in prostate cancer mortality in specific subgroups of men may be due to screening | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use (...) be due to screening Article Text Therapeutics/Prevention Randomised controlled trial Although the evidence is not clear, decreases in prostate cancer mortality in specific subgroups of men may be due to screening Dragan Ilic 1 , Philipp Dahm 2 Statistics from Altmetric.com Commentary on : Schröder F , Hugosson J , Roobol M , et al . ERSPC Investigators. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up

2015 Evidence-Based Medicine

26. Recommendations on screening for prostate cancer with the prostate-specific antigen test Full Text available with Trip Pro

Recommendations on screening for prostate cancer with the prostate-specific antigen test 25349003 2015 01 22 2018 11 13 1488-2329 186 16 2014 11 04 CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne CMAJ Recommendations on screening for prostate cancer with the prostate-specific antigen test. 1225-34 10.1503/cmaj.140703 Bell Neil N Department of Family Medicine (Bell), University of Alberta, Edmonton, Alta.; Public Health Agency of Canada (Connor Gorber (...) Early Detection of Cancer methods Humans Male Prostate-Specific Antigen blood Prostatic Neoplasms diagnosis mortality Tonelli Marcello M Birtwhistle Richard R Bacchus Maria M Bell Neil N Brauer Paula P Dickinson James J Grad Roland R Lewin Gabriela G Moore Ainsley A Parkin Patricia P Pottie Kevin K Singh Harminder H Thombs Brett David BD 2014 10 29 6 0 2014 10 29 6 0 2015 1 23 6 0 ppublish 25349003 cmaj.140703 10.1503/cmaj.140703 PMC4216256 BMJ. 2012;345:e6572 23137819 Cancer. 2003 Apr 1;97(7):1653

2014 EvidenceUpdates

27. A simple schema for informed decision-making about prostate cancer screening Full Text available with Trip Pro

A simple schema for informed decision-making about prostate cancer screening 25222389 2014 11 12 2018 11 13 1539-3704 161 6 2014 Sep 16 Annals of internal medicine Ann. Intern. Med. A simple schema for informed decision making about prostate cancer screening. 441-2 10.7326/M14-0151 Vickers Andrew J AJ Edwards Kelly K Cooperberg Matthew R MR Mushlin Alvin I AI eng 1-U48-DP-000050 DP NCCDPHP CDC HHS United States UL1 RR024996 RR NCRR NIH HHS United States P50-CA92629 CA NCI NIH HHS United States (...) (6):457 25775324 Ann Intern Med. 2015 Mar 17;162(6):457-8 25775325 Decision Making Early Detection of Cancer methods Humans Male Patient Education as Topic Patient Participation Primary Health Care Prostate-Specific Antigen blood Prostatic Neoplasms diagnosis 2014 9 16 6 0 2014 9 16 6 0 2014 11 13 6 0 ppublish 25222389 1905132 10.7326/M14-0151 PMC4412472 NIHMS683463 Ann Intern Med. 2010 Nov 16;153(10):661-5 21079223 JAMA. 2011 Dec 28;306(24):2721-2 22203543 J Clin Oncol. 2012 Jul 20;30(21):2581-4

2014 Annals of Internal Medicine

28. Self-screening for prostate cancer: ban in France is justified

Self-screening for prostate cancer: ban in France is justified Prescrire IN ENGLISH - Spotlight ''Self-screening for prostate cancer: ban in France is justified'', 1 September 2013 {1} {1} {1} | | > > > Self-screening for prostate cancer: ban in France is justified Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Self-screening for prostate cancer (...) : ban in France is justified Screening for prostate cancer by measuring PSA levels presents an unfavourable harm-benefit balance. Measuring the level of the prostate specific antigen (PSA) in the blood is used in prostate cancer screening. In September 2012, the French Health Products Safety Agency banned the sale of PSA self-testing kits in France. Used in a non-medical environment, particularly in the home, these tests measure PSA levels in the blood from a drop of capillary blood. Independently

2014 Prescrire

29. Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study. Full Text available with Trip Pro

Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study. To determine the relative risks of prostate cancer incidence, metastasis, and mortality associated with screening by serum prostate specific antigen (PSA) levels at age 60.Population based cohort study.General male population of Sweden taking part in a screening trial in Gothenburg or participating in a cardiovascular study, the Malmö Preventive (...) Project.The screened group consisted of 1756 men aged 57.5-62.5 participating in the screening arm of the Gothenburg randomized prostate cancer screening trial since 1995. The unscreened group consisted of 1162 men, born in 1921, participating in the Malmö Preventive Project, with PSA levels measured retrospectively in stored blood samples from 1981.PSA screening versus no screening.Incidence rate ratios for the effect of screening on prostate cancer diagnosis, metastasis, and death by PSA levels at age

2014 BMJ

30. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. Full Text available with Trip Pro

Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. Prostate cancer screening with the prostate-specific antigen (PSA) test remains controversial.To review evidence from randomized trials and related modeling studies examining the effect of PSA screening vs no screening on prostate cancer-specific mortality and to suggest an approach balancing potential benefits and harms.MEDLINE, EMBASE, and the Cochrane Register of Controlled Trials were (...) searched from January 1, 2010, to April 3, 2013, for PSA screening trials to update a previous systematic review. Another search was performed in EMBASE and MEDLINE to identify modeling studies extending the results of the 2 large randomized trials identified. The American Heart Association Evidence-Based Scoring System was used to rate level of evidence.Two trials-the Prostate, Lung, Colorectal and Ovarian (PLCO) screening trial and the European Randomized Study of Screening for Prostate Cancer (ERSPC

2014 JAMA

31. Cohort study: A targeted approach reduces prostate cancer-specific (PSA) screening harms while preserving benefits

cancer-specific (PSA) screening harms while preserving benefits Amanda Black Statistics from Altmetric.com Commentary on: Carlsson S , Assel M , Sjoberg D , et al . Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study . Context Prostate-specific antigen (PSA) screening for prostate cancer may prevent some men dying from the disease. 1 However, had they not been screened, many contemporary men diagnosed (...) with prostate cancer would never have experienced symptoms or died from their cancer. Considering the devastating impact of an unnecessary cancer diagnosis and treatment-associated sequelae, PSA screening as it is currently used arguably results in greater harm than good. Nevertheless, PSA is entrenched in healthcare systems across the globe and, until we identify another test that can accurately discriminate the few potentially fatal malignancies from the many more indolent prostate cancers, PSA screening

2014 Evidence-Based Medicine

32. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Full Text available with Trip Pro

Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. The European Randomised study of Screening for Prostate Cancer (ERSPC) has shown significant reductions in prostate cancer mortality after 9 years and 11 years of follow-up, but screening is controversial because of adverse events such as overdiagnosis. We provide updated results of mortality from prostate cancer with follow-up to 2010 (...) randomised, which is equivalent to one prostate cancer death averted per 781 (95% CI 490-1929) men invited for screening or one per 27 (17-66) additional prostate cancer detected. After adjustment for non-participation, the rate ratio of prostate cancer mortality in men screened was 0·73 (95% CI 0·61-0·88).In this update the ERSPC confirms a substantial reduction in prostate cancer mortality attributable to testing of PSA, with a substantially increased absolute effect at 13 years compared with findings

2014 Lancet Controlled trial quality: predicted high

33. [Summary of the exploration of the scientific literature on the effects of prostate cancer screening decision aids for the expert panel of the Collège des médecins du Québec]

of the scientific literature on the effects of prostate cancer screening decision aids for the expert panel of the Collège des médecins du Québec] Quebec: Institut national d'excellence en sante et en services sociaux (INESSS). 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Decision Support Techniques; Humans; Mass Screening; Prostatic Neoplasms Language Published French Country of organisation Canada Province or state Quebec English summary An English language summary (...) [Summary of the exploration of the scientific literature on the effects of prostate cancer screening decision aids for the expert panel of the Collège des médecins du Québec] Résumé de l'exploration de la littérature scientifique sur les effets des outils d'aide à la décision pour les patients portant sur le dépistage du cancer de la prostate pour le comité d'experts du Collège des médecins du Québec [Summary of the exploration of the scientific literature on the effects of prostate cancer

2014 Health Technology Assessment (HTA) Database.

34. Decision Making in Prostate Cancer Screening Using Decision Aids vs Usual Care: A Randomized Clinical Trial Full Text available with Trip Pro

Decision Making in Prostate Cancer Screening Using Decision Aids vs Usual Care: A Randomized Clinical Trial The conflicting recommendations for prostate cancer (PCa) screening and the mixed messages communicated to the public about screening effectiveness make it critical to assist men in making informed decisions.To assess the effectiveness of 2 decision aids in helping men make informed PCa screening decisions.A racially diverse group of male outpatients aged 45 to 70 years from 3 sites were (...) interviewed by telephone at baseline, 1 month, and 13 months, from 2007 through 2011. We conducted intention-to-treat univariate analyses and multivariable linear and logistic regression analyses, adjusting for baseline outcome measures.Random assignment to print-based decision aid (n = 628), web-based interactive decision aid (n = 625), or usual care (UC) (n = 626).Prostate cancer knowledge, decisional conflict, decisional satisfaction, and whether participants underwent PCa screening.Of 4794 eligible

2013 EvidenceUpdates Controlled trial quality: predicted high

35. Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening. Full Text available with Trip Pro

Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening. Knowledge of the likelihood that a screening-detected case of cancer has been overdiagnosed is vitally important to make treatment decisions and develop screening policy. An overdiagnosed case is an excess case detected by screening. Estimates of the frequency of overdiagnosis in breast and prostate cancer screening vary greatly across studies. This article identifies features (...) of overdiagnosis studies that influence results and shows their effect by using published research. First, different ways to define and measure overdiagnosis are considered. Second, contextual features and how they affect overdiagnosis estimates are examined. Third, the effect of estimation approach is discussed. Many studies use excess incidence under screening as a proxy for overdiagnosis. Others use statistical models to make inferences about lead time or natural history and then derive the corresponding

2013 Annals of Internal Medicine

36. Screening for Prostate Cancer: A Guidance Statement From the Clinical Guidelines Committee of the American College of Physicians. Full Text available with Trip Pro

Screening for Prostate Cancer: A Guidance Statement From the Clinical Guidelines Committee of the American College of Physicians. Prostate cancer is an important health problem in men. It rarely causes death in men younger than 50 years; most deaths associated with it occur in men older than 75 years. The benefits of screening with the prostate-specific antigen (PSA) test are outweighed by the harms for most men. Prostate cancer never becomes clinically significant in a patient's lifetime (...) in a considerable proportion of men with prostate cancer detected with the PSA test. They will receive no benefit and are subject to substantial harms from the treatment of prostate cancer. The American College of Physicians (ACP) developed this guidance statement for clinicians by assessing current prostate cancer screening guidelines developed by other organizations. ACP believes that it is more valuable to provide clinicians with a rigorous review of available guidelines rather than develop a new guideline

2013 Annals of Internal Medicine

37. Guidance Statement: Screening for Prostate Cancer: A Guidance Statement from the American College of Physicians Full Text available with Trip Pro

of PSA testing in addition to age-specific reference ranges that should be considered when evaluating the results for serum PSA. It discusses the association between elevated serum PSA levels with common prostatic diseases, such as prostatitis, benign prostatic hyperplasia, and prostate cancer. The guideline notes the harms of screening. The AUA's recommendation to begin baseline testing at age 40 years is not based on data from clinical trials. In addition, the guideline does not specify a threshold (...) will die of prostate cancer (or 5 in 100 for African American men), this means that 97 in 100 men (or 95 in 100 African American men) will die of something else. Finally, although some men may avoid pain and discomfort commonly associated with advanced disease, this must be balanced against the possibility of incontinence, erectile dysfunction, and other side effects that result from certain forms of aggressive treatment. The goal of screening for any disease is to identify an undiagnosed condition

2013 American College of Physicians

38. Prostate cancer screening: a review of the guidelines

Prostate cancer screening: a review of the guidelines Prostate cancer screening: a review of the guidelines Prostate cancer screening: a review of the guidelines CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Prostate cancer screening: a review of the guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (...) (CADTH). Rapid Response - Summary with Critical Appraisal. 2013 Authors' conclusions Ten North American guidelines on prostate cancer screening were included in the review. The ten guidelines agreed on recommending prostate cancer screening for men but the age at which screening was recommended differed between guidelines. Six guidelines gave positive recommendations for using PSA-based screening, while one guideline recommended against this practice. This disagreement was due to difference

2013 Health Technology Assessment (HTA) Database.

39. Systematic review: Review of evidence concerning PSA screening for prostate cancer has limitations as basis for policy development

Systematic review: Review of evidence concerning PSA screening for prostate cancer has limitations as basis for policy development Review of evidence concerning PSA screening for prostate cancer has limitations as basis for policy development | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review of evidence concerning PSA screening for prostate cancer has limitations as basis for policy development Article Text Diagnosis Systematic

2013 Evidence-Based Medicine

40. Population screening for prostate cancer: an overview of available studies and meta-analysis

Population screening for prostate cancer: an overview of available studies and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.